265 related articles for article (PubMed ID: 27126691)
21. Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.
Al-Din Y; Dryden C; MacGregor G; Young D; Coelho C
Clin Respir J; 2023 May; 17(5):473-477. PubMed ID: 36938952
[TBL] [Abstract][Full Text] [Related]
22. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
23. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
25. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
26. Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.
Bell SC; Mainz JG; MacGregor G; Madge S; Macey J; Fridman M; Suthoff ED; Narayanan S; Kinnman N
BMC Pulm Med; 2019 Aug; 19(1):146. PubMed ID: 31409396
[TBL] [Abstract][Full Text] [Related]
27. Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy.
Zhou GC; Wang Z; Palipana AK; Andrinopoulou ER; Miranda Afonso P; McPhail GL; Siracusa CM; Gecili E; Szczesniak RD
Respir Res; 2024 Apr; 25(1):187. PubMed ID: 38678203
[TBL] [Abstract][Full Text] [Related]
28. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
[TBL] [Abstract][Full Text] [Related]
29. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
30. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience.
Durmowicz AG; Witzmann KA; Rosebraugh CJ; Chowdhury BA
Chest; 2013 Jan; 143(1):14-18. PubMed ID: 23276841
[TBL] [Abstract][Full Text] [Related]
31. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.
Barry PJ; Plant BJ; Nair A; Bicknell S; Simmonds NJ; Bell NJ; Shafi NT; Daniels T; Shelmerdine S; Felton I; Gunaratnam C; Jones AM; Horsley AR
Chest; 2014 Jul; 146(1):152-158. PubMed ID: 24522694
[TBL] [Abstract][Full Text] [Related]
32. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
33. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
[TBL] [Abstract][Full Text] [Related]
34. Cystic fibrosis in an era of genomically guided therapy.
Barrett PM; Alagely A; Topol EJ
Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
[TBL] [Abstract][Full Text] [Related]
35. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
[TBL] [Abstract][Full Text] [Related]
36. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
37. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
[TBL] [Abstract][Full Text] [Related]
39. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
[TBL] [Abstract][Full Text] [Related]
40. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
Dryden C; Wilkinson J; Young D; Brooker RJ;
Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
